

Third Program In The Series

Ensuring Subject Protection and Scientific Integrity

Course Introduction Monitoring of Clinical Studies

Introduction Site Initiation Visit: Initiation Visit Planning Site Initiation Visit: Conducting the Initiation Visit Site Initiation Visit: Initiation Visit Follow-up **Routine Monitoring Visits** How Much Data Needs To Be Monitored? Final Monitoring Visit Changing Data in Case Report Forms Monitoring Reporting Requirements

Clinical Quality Assurance (CQA)

Introduction Typical CQA Group CQA Audits **GCP** Audits Data Evaluation Investigator Site Audit

FDA Inspections

Clinical Trial Monitoring Noncompliance Issues **Regulations Guiding Inspections** Non-US Inspections What FDA Will Inspect **Common Deficiencies** Inspection Results Managing FDA Inspections **IRB/EC and CRO Inspections**

Course Authors

Carol Nash Michael Carter, MD, RP Sr. Director, Clinical Safety & Pharmacovigilance URL Pharma, Inc.